BGLC vs. RNLX, XGN, PMD, DMTK, FRES, OPGN, ACON, NVTA, CNTG, and LH
Should you be buying BioNexus Gene Lab stock or one of its competitors? The main competitors of BioNexus Gene Lab include Renalytix (RNLX), Exagen (XGN), Psychemedics (PMD), DermTech (DMTK), Fresh2 Group (FRES), OpGen (OPGN), Aclarion (ACON), Invitae (NVTA), Centogene (CNTG), and Laboratory Co. of America (LH). These companies are all part of the "medical laboratories" industry.
Renalytix (NASDAQ:RNLX) and BioNexus Gene Lab (NASDAQ:BGLC) are both small-cap computer and technology companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.
9.9% of Renalytix shares are owned by institutional investors. Comparatively, 18.9% of BioNexus Gene Lab shares are owned by institutional investors. 17.8% of Renalytix shares are owned by insiders. Comparatively, 6.8% of BioNexus Gene Lab shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Renalytix presently has a consensus price target of $5.00, suggesting a potential upside of 986.25%. Given BioNexus Gene Lab's higher probable upside, research analysts clearly believe Renalytix is more favorable than BioNexus Gene Lab.
Renalytix received 8 more outperform votes than BioNexus Gene Lab when rated by MarketBeat users.
BioNexus Gene Lab has a net margin of -27.24% compared to BioNexus Gene Lab's net margin of -1,687.80%. Renalytix's return on equity of -30.74% beat BioNexus Gene Lab's return on equity.
BioNexus Gene Lab has higher revenue and earnings than Renalytix.
In the previous week, BioNexus Gene Lab had 1 more articles in the media than Renalytix. MarketBeat recorded 1 mentions for BioNexus Gene Lab and 0 mentions for Renalytix. BioNexus Gene Lab's average media sentiment score of 0.00 equaled Renalytix'saverage media sentiment score.
Summary
BioNexus Gene Lab beats Renalytix on 7 of the 12 factors compared between the two stocks.
Get BioNexus Gene Lab News Delivered to You Automatically
Sign up to receive the latest news and ratings for BGLC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BGLC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioNexus Gene Lab Competitors List
Related Companies and Tools
